These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22984269)

  • 1. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
    Roll P; Ostermeier E; Haubitz M; Lovric S; Unger L; Holle J; Kötter I; Henes JC; Bergner R; Rubbert-Roth A; Specker C; Schulze-Koops H; Müller-Ladner U; Fleck M; Burmester GR; Hiepe F; Heitmann S; Aringer M; Fischer-Betz R; Dörner T; Tony HP
    J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
    Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
    Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
    Cartin-Ceba R; Fervenza FC; Specks U
    Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in ANCA-associated vasculitis: fad or fact?
    Fervenza FC
    Nephron Clin Pract; 2011; 118(2):c182-8; discussion c188. PubMed ID: 21160229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for ANCA-associated vasculitis in the setting of severe infection.
    Gregersen JW; Chaudhry A; Jayne DR
    Scand J Rheumatol; 2013; 42(3):207-10. PubMed ID: 23286789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.
    Venhoff N; Niessen L; Kreuzaler M; Rolink AG; Hässler F; Rizzi M; Voll RE; Thiel J
    Autoimmunity; 2014 Sep; 47(6):401-8. PubMed ID: 24798501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.
    Roubaud-Baudron C; Pagnoux C; Méaux-Ruault N; Grasland A; Zoulim A; LE Guen J; Prud'homme A; Bienvenu B; de Menthon M; Camps S; LE Guern V; Aouba A; Cohen P; Mouthon L; Guillevin L;
    J Rheumatol; 2012 Jan; 39(1):125-30. PubMed ID: 22089465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)].
    Venhoff N; Proft F; Schulze-Koops H; Holle J; Voll RE; Iking-Konert C; Jacobi AM; Henes J; Unger L; Kneitz O; Dörner T; Thiel J
    Z Rheumatol; 2018 Feb; 77(1):21-27. PubMed ID: 28508096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
    Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
    Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
    Besada E; Koldingsnes W; Nossent JC
    Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
    Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U
    Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
    Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients.
    Moog P; Probst M; Kuechle C; Hauser C; Heemann U; Thuermel K
    Scand J Rheumatol; 2014; 43(6):519-23. PubMed ID: 25179776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.